BioLineRx (NASDAQ:BLRX) Stock Passes Above Two Hundred Day Moving Average – Here’s Why

BioLineRx Ltd. (NASDAQ:BLRX) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.87 and traded as high as $3.05. BioLineRx shares last traded at $3.01, with a volume of 221,991 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioLineRx in a research report on Monday, April 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

BioLineRx Stock Performance

The firm has a market cap of $13.50 million, a P/E ratio of -1.61 and a beta of 1.55. The stock’s 50 day moving average is $3.16 and its two-hundred day moving average is $2.87. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.58 and a quick ratio of 1.43.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings data on Wednesday, May 27th. The biotechnology company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.68. BioLineRx had a negative return on equity of 37.73% and a negative net margin of 563.70%.The company had revenue of $0.48 million for the quarter, compared to the consensus estimate of $0.34 million.

About BioLineRx

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.